Back
BioCryst Pharmaceuticals 10K Form
Sell
35
BCRX
BioCryst Pharmaceuticals
Last Price:
8.16
Seasonality Move:
-9.69%
7 Day Trial
ALL ACCESS PASS
$
7
Key Filings
| 2024-05-07 | 10Q | BCRX/BioCryst Pharmaceuticals Quarterly |
| 2023-11-08 | 10Q | BCRX/BioCryst Pharmaceuticals Quarterly |
| 2023-08-07 | 10Q | BCRX/BioCryst Pharmaceuticals Quarterly |
| 2023-05-08 | 10Q | BCRX/BioCryst Pharmaceuticals Quarterly |
| 2022-11-04 | 10Q | BCRX/BioCryst Pharmaceuticals Quarterly |
| 2022-08-05 | 10Q | BCRX/BioCryst Pharmaceuticals Quarterly |
Receive BCRX News And Ratings
See the #1 stock for the next 7 days that we like better than BCRX
BCRX Financial Statistics
Sales & Book Value
| Annual Sales: | $331.41M |
|---|---|
| Cash Flow: | $-1.52M |
| Price / Cash Flow: | 0 |
| Annual Sales: | $-2.30 |
| Price / Book: | 0 |
Profitability
| EPS (TTM): | -0.73000 |
|---|---|
| Net Income (TTM): | $-145.93M |
| Gross Margin: | $326.75M |
| Return on Equity: | 0% |
| Return on Assets: | -29.07% |
BioCryst Pharmaceuticals Earnings Forecast
Key BioCryst Pharmaceuticals Financial Ratios
- The Gross Profit Margin over the past 30 years for BCRX is 98.59%.
- The Selling, General & Administrative Expenses for BCRX have been equal to 64.54% of Gross Profit Margin.
- The Research & Development expenses have been 65.35% of Revenue.
- The Interest Expense is -47.78% of Operating Income.
- The Net Earning history of BCRX is -68.36% of Total Revenues.
- Per Share Earnings over the last 30 years have been positive in 14 years.
BioCryst Pharmaceuticals Stock Price Chart
Industry, Sector and Symbol
| Stock Exchange: | NASDAQ |
|---|---|
| Industry: | Biotechnology |
| Sector: | Health Care |
| Current Symbol: | BCRX |
| CUSIP: | 09058V |
| Website: | biocryst.com |
Debt
| Debt-to-Equity Ratio: | -1.7 |
|---|---|
| Current Ratio: | 2.82 |
| Quick Ratio: | 2.64 |
Price-to-Earnings
| Trailing P/E Ratio: | 0 |
|---|---|
| Forward P/E Ratio: | 0 |
BCRX Technical Analysis vs Fundamental Analysis
Sell
35
BioCryst Pharmaceuticals (BCRX)
is a Sell
Is BioCryst Pharmaceuticals a Buy or a Sell?
-
BioCryst Pharmaceuticals stock is rated a Sell
The current BioCryst Pharmaceuticals [BCRX] share price is $7.97. The Score for BCRX is 35, which is 30% below its historic median score of 50, and infers higher risk than normal.